Gencurix’s endometrial cancer mutation 바카라 온라인 demonstrates diagnostic accuracy and speed in UK NSH clinical trial
- Results delivered in an average of seven days… 바카라 온라인 speed shortened by two weeks compared to NGS - Clinical results were unveiled at the European Society of Genetics in Milan, Italy
[by Ji, Yong Jun] Gencurix, a company specializing in cancer molecular diagnostics, announced on May 23 that its endometrial cancer diagnostic product, the ‘Droplex POLE Mutation 바카라 온라인,’ demonstrated diagnostic accuracy and rapid turnaround time in clinical trials conducted at hospitals affiliated with the United Kingdom’s National Health Service (NHS).
The 바카라 온라인 trial was jointly conducted by Sheffield Children’s Hospital and Leeds St. James’s University Hospital in the UK. The findings from the study will be presented in poster format at the European Society of Human Genetics (ESHG 2025) conference, scheduled to take place in Milan, Italy, on May 24.
The clinical trial results showed that Gencurix’s Droplex POLE Mutation 바카라 온라인 delivered results in an average of seven days, with the fas바카라 온라인 turnaround in just four days, approximately two weeks faster than conventional next-generation sequencing (NGS) methods. In addition, the company explained that the 바카라 온라인 demonstrated 100% accuracy and sensitivity and maintained high reproducibility even with low-concentration DNA samples, thereby confirming its reliability for diagnostic use.
The ‘POLE gene’ mutation is an important biomarker for predicting the prognosis of endometrial cancer patients. Patients who 바카라 온라인 positive for the mutations are classified as low-risk (POLEmut) and may be able to avoid unnecessary chemotherapy. Conversely, patients without the mutation can proceed with early precision 바카라 온라인ing and transition to active treatment. Therefore, the speed and accuracy of diagnosis are essential components in implementing an effective personalized treatment strategy.
The World Health Organization (WHO), the National Comprehensive Cancer Network (NCCN), the European Society for Medical Oncology (ESMO), and the International Federation of Gynecology and Obstetrics (FIGO) all recommend POLE gene mutation 바카라 온라인ing for the diagnosis and personalized treatment of endometrial cancer patients.
Gencurix’s POLE mutation 바카라 온라인 is the world’s first commercialized diagnostic product utilizing digital PCR technology. In March 2024, it was designated by the Ministry of Health and Welfare as a target for the ‘New Medical Technology Evaluation Delay’ program. The 바카라 온라인 has since received in vitro diagnostic certification (CE-IVD) in Europe and regulatory approval from the Ministry of Food and Drug Safety in Korea. Leveraging this, Gencurix is currently providing 바카라 온라인ing services to approximately 30 general hospitals in Korea and exporting the diagnostic product to countries in Europe and Asia.
“These clinical results are an example demonstrating not only the diagnostic accuracy of the Droplex POLE mutation 바카라 온라인, but also its clinical utility and market competitiveness,” stated Jeong Jong-seok, head of the Global Business Division at Gencurix. “We plan to further solidify our position as a global leader in the field of cancer precision diagnostics,” he added.